Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

Last updated: December 22, 2015
Sponsor: Memorial Sloan Kettering Cancer Center
Overall Status: Completed

Phase

N/A

Condition

Colon Cancer; Rectal Cancer

Colorectal Cancer

Cancer

Treatment

N/A

Clinical Study ID

NCT00550628
07-114
MSKCC-07114
P30CA008748
  • Ages > 15
  • All Genders

Study Summary

RATIONALE: Diagnostic imaging procedures, such as fludeoxyglucose F 18 PET, may be effective in detecting cancer or recurrence of cancer, or premalignant polyps.

PURPOSE: This clinical trial is studying fludeoxyglucose F 18-PET imaging to see how well it works in determining protein and gene expression signatures in patients with premalignant polyps or colon cancer.

Eligibility Criteria

Inclusion

Subject Inclusion Criteria:

  • Patients eligible for entry into the study are those:

  • Age 15 to 100

  • Undergoing resection of a non-sarcomatous primary colon neoplasm who also has 2 ormore adenomas each greater than or equal to 7-10mm in size which are anticipated to beremoved with the colon specimen.

  • It will be known from MSKCC or outside studies (barium enema, endoscopy, PET/CT, or CTcolonography) that the patient has at least 2 proven adenomas 7-10 mm or greater and aprimary colon neoplasm

Exclusion

Subject Exclusion Criteria:

  • Insulin-dependent diabetics (as established by routine history and presurgicallaboratory tests).

Study Design

Total Participants: 8
Study Start date:
September 01, 2007
Estimated Completion Date:
September 30, 2011

Study Description

OBJECTIVES:

Primary

  • To determine the feasibility of ex-vivo imaging of colon cancer and colon polyps using fludeoxyglucose F 18 positron emission tomography (FDG PET).

  • To evaluate the differences in molecular and genetic profiles between FDG-positive polyps and FDG-negative polyps to suggest what gene mutations and abnormal mRNA and/or protein expressions may be required for FDG avidity ("signature" for FDG avidity).

Secondary

  • To evaluate the differences in molecular and genetic profiles between FDG-positive polyps and FDG-positive cancers to suggest what gene mutations and abnormal mRNA and/or protein expressions may be required for cancer formation ("signature" for cancer).

  • To evaluate the differences in molecular and genetic profiles between normal colonic mucosa, polyps, and cancer.

  • To evaluate the differences and similarities in molecular and genetic profiles between FDG-positive cancers and polyps.

OUTLINE: Part I: Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by surgery to remove part or all of the colon. Tissue samples of the colon undergo positron emission tomography (PET) imaging.

Part II: Tissue samples are analyzed for glucose transporters proteins (Glut-1, 2, 3, 4, 5, 7) via IHC; presence of K-ras mutation (invariable mutant site on codon 12, 13) via PCR; 18q deletion via fluorescence in situ hybridization (FISH) or DCC IHC; MCT-1, Hex-1, Hex-2, and COX-2 expression levels via quantitative RT-PCR method or western blot; APC mutation via PCR- In Vitro Synthesized-Protein Assay or RT-PCR direct sequencing method; p53 mutation detection via immunochemistry, RT-PCR direct sequence methods, and western blot; methylation alteration of MGMT, CDKN2A, HLTF, MLH1, TIMP3, HIF1, BNIP3, and HRK via methylation detecting microchip; and specific gene methylations via methylation-specific PCR. Some tissue samples may be saved and banked for future studies.

Connect with a study center

  • Memorial Sloan-Kettering Cancer Center

    New York, New York 10065
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.